Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 43.1
edited by manuelmenendez
on 2025/02/05 11:14
on 2025/02/05 11:14
Change comment:
There is no comment for this version
To version 34.1
edited by manuelmenendez
on 2025/02/01 13:54
on 2025/02/01 13:54
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,9 +2,9 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= //A new tridimensional diagnostic framework for complexCNS diseases// =5 += //A new tridimensional diagnostic framework for CNS diseases// = 6 6 7 -This project is focused on developing a novel nosological and diagnostic framework for complexCNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.7 +This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 8 We aim to create a structured, interpretable, and scalable diagnostic tool. 9 9 ))) 10 10 ))) ... ... @@ -18,46 +18,38 @@ 18 18 = **Overview** = 19 19 20 20 21 -The classification and diagnosis of central nervous system (CNS) diseases have long been constrained by traditional ,phenotype-based approachesthatoften fail to capture the complexinterplay of pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes.NeurodiagnosesredefinesthislandscapebyintegratingadvancedAI withmulti-modal data—including genetics,neuroimaging, biomarkers,anddigitalhealthrecords—tocreatea moreprecise,scalable, anddata-driven diagnostic system.21 +The classification and diagnosis of **central nervous system (CNS) diseases** have long been constrained by **traditional phenotype-based approaches**, which often fail to capture the **complex pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes** that drive disease progression. **Neurodegenerative and psychiatric disorders**, for example, exhibit significant **clinical overlap, co-pathology, and heterogeneity**, making current diagnostic models insufficient. 22 22 23 - In additiontotheseclinicaldiagnosticapproaches, Neurodiagnoseshas expanded intoa research-orientedplatform through the integrationof**CNSDigitalTwins**. This cutting-edge conceptinvolves creatinga personalizeddigital replicaofapatient’sCNS by incorporatingmulti-omicsdata (proteomics,genomics,lipidomics,transcriptomics), variousneuroimagingmodalities, and digitalhealth information. Thesedigital twinsenablesimulations ofdiseaseprogression,support thediscoveryof novelbiomarkers, andhelpidentify newtherapeutictargets.23 +This project proposes a **new diagnostic framework**—one that **shifts from symptom-based classifications** to an **etiology-driven, tridimensional system**. By integrating **genetics, proteomics, neuroimaging, computational modeling, and AI-powered annotations**, this approach aims to provide a **more precise, scalable, and biologically grounded method for diagnosing and managing CNS diseases**. 24 24 25 - Onthis page,youwillfind:25 +The **AI-powered annotation system** plays a critical role by **structuring, interpreting, and tracking multi-modal data**, ensuring **real-time disease progression analysis, clinician decision support, and personalized treatment pathways**. 26 26 27 -* Detailed descriptions of both the clinical diagnostic tools and the research framework. 28 -* Access to our AI models, data processing pipelines, and digital twin simulations. 29 -* Collaborative resources for researchers, clinicians, and AI developers. 30 -* Guidelines and instructions on how to contribute to and expand the project. 27 +=== **Project Aim** === 31 31 29 +The project aims to develop a **tridimensional diagnostic framework** with an **AI-powered annotation system**, integrating **etiology, molecular biomarkers, and neuroanatomoclinical correlations** for **precise, standardized, and scalable CNS disease diagnostics**. 32 32 33 - == **The roleofAI-powered annotation**==31 +The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on: 34 34 35 -To enhance standardization, interpretability, and clinical application, the framework integrates an AI-powered annotation system, which: 33 +* **Axis 1**: Etiology (genetic or other causes of diseases). 34 +* **Axis 2**: Molecular Markers (biomarkers). 35 +* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 36 36 37 -* Assign structured metadata tags to diagnostic features. 38 -* Provides real-time contextual explanations for AI-based classifications. 39 -* Tracks longitudinal disease progression using timestamped AI annotations. 40 -* Improves AI model transparency through interpretability tools (e.g., SHAP analysis). 41 -* Facilitates decision-making for clinicians by linking annotations to standardized biomedical ontologies (SNOMED, HPO). 37 +This methodology enables: 42 42 43 -Neurodiagnoses provides two complementary AI-driven diagnostic approaches: 39 +* Greater precision in diagnosis. 40 +* Integration of incomplete datasets using AI-driven probabilistic modeling. 41 +* Stratification of patients for personalized treatment. 44 44 45 - 1.Traditional Probabilistic Diagnosis43 +== **The Role of AI-Powered Annotation** == 46 46 47 -* AI provides multiple possible diagnoses, each assigned a probability percentage based on biomarker, imaging, and clinical data. 48 -* Useful for differential diagnosis and treatment decision-making. 45 +To enhance **standardization, interpretability, and clinical application**, the framework integrates **an AI-powered annotation system**, which: 49 49 50 -2. Tridimensional Diagnosis 47 +* **Assigns structured metadata tags** to diagnostic features. 48 +* **Provides real-time contextual explanations** for AI-based classifications. 49 +* **Tracks longitudinal disease progression** using timestamped AI annotations. 50 +* **Improves AI model transparency** through interpretability tools (e.g., SHAP analysis). 51 +* **Facilitates decision-making for clinicians** by linking annotations to standardized biomedical ontologies (SNOMED, HPO). 51 51 52 -* Diagnoses are structured based on: 53 -(1) Etiology (genetic, autoimmune, metabolic, infectious) 54 -(2) Molecular Biomarkers (amyloid-beta, tau, inflammatory markers, EEG patterns) 55 -(3) Neuroanatomoclinical Correlations (brain atrophy, connectivity alterations) 56 -* This approach enables precise disease subtyping and biologically meaningful classification, particularly useful for tracking progression over time. 57 - 58 -Both systems will be offered for every patient case, allowing clinicians to compare AI-generated probabilistic diagnosis with a structured tridimensional classification. 59 - 60 - 61 61 == **The case of neurodegenerative diseases** == 62 62 63 63 There have been described these 3 diagnostic axes: ... ... @@ -70,8 +70,6 @@ 70 70 * //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. 71 71 * //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. 72 72 * //Tests//: Genetic testing, lifestyle, and cardiovascular screening. 73 - 74 - 75 75 ))) 76 76 * ((( 77 77 **Axis 2: Molecular Markers** ... ... @@ -79,8 +79,6 @@ 79 79 * //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. 80 80 * //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. 81 81 * //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). 82 - 83 - 84 84 ))) 85 85 * ((( 86 86 **Axis 3: Neuroanatomoclinical** ... ... @@ -108,13 +108,10 @@ 108 108 * Develop interpretable AI models for diagnosis and progression tracking. 109 109 * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. 110 110 * Foster collaboration among neuroscientists, AI researchers, and clinicians. 111 -* Provide a dual diagnostic system: 112 -** Probabilistic Diagnosis – AI assigns multiple traditional possible diagnoses with probability percentages. 113 -** Tridimensional Diagnosis – AI structures diagnoses based on etiology, biomarkers, and neuroanatomical correlations. 114 114 115 115 == Who has access? == 116 116 117 -We welcome contributions from the global community. Join us as we transform CNS diagnostics and drive precision medicine forward through a collaborative, open-source approach.Let’s build the future of neurological diagnostics together!102 +We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 118 118 ))) 119 119 120 120 ... ... @@ -135,7 +135,6 @@ 135 135 * `/data`: Sample datasets for testing. 136 136 * `/outputs`: Generated models, visualizations, and reports. 137 137 * [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]] 138 -* [[Notebooks>>Notebooks]] 139 139 * [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]] 140 140 * [[to-do-list>>to-do-list]] 141 141 )))